文献速递淋巴瘤造血干细胞移植与细胞治疗

GVHD对淋巴瘤进展的影响:日本移植与细胞治疗学会全国性研究

Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy.
PubMed 文献 · Br J Haematol · 2023-08-23

该回顾性研究分析2003-2017年日本2204例首次接受异基因造血干细胞移植的非霍奇金淋巴瘤患者,评估急慢性GVHD对淋巴瘤进展的影响。总体队列中GVHD对淋巴瘤进展无统计学影响,但特定亚组中影响明确,支持存在与GVHD相关的移植物抗淋巴瘤效应。

要点

  • 总体队列中aGVHD/cGVHD对淋巴瘤进展无统计学影响,但特定亚组影响明确
  • CR患者中I-II级aGVHD与淋巴瘤进展风险降低相关(HR 0.63,95%CI 0.43-0.91)
  • 广泛型cGVHD对成熟侵袭性B细胞淋巴瘤患者有影响(HR 0.55,95%CI 0.31-0.97)

核心结论

  • 总体队列中aGVHD/cGVHD对淋巴瘤进展无统计学影响,但在特定淋巴瘤亚型/移植前控制状态组中影响明确,支持存在与GVHD相关的移植物抗淋巴瘤效应。
  • 作者建议将GVHD控制在有限活动度内,考虑到严重GVHD的负面影响。
  • 移植前淋巴瘤控制仍是影响移植结局的强因素,改善其管理是重要议题。

研究设计与样本

  • 回顾性分析2003-2017年日本2204例首次接受异基因造血干细胞移植的非霍奇金淋巴瘤患者。
  • 惰性B细胞非霍奇金淋巴瘤689例,侵袭性B细胞非霍奇金淋巴瘤720例,成熟T/NK细胞非霍奇金淋巴瘤795例。
  • 移植前淋巴瘤控制:完全缓解759例,非完全缓解1445例。

主要发现

  • 总体队列中aGVHD/cGVHD对淋巴瘤进展无统计学影响。
  • 完全缓解患者中I-II级aGVHD与淋巴瘤进展风险降低相关(HR 0.63,95%CI 0.43-0.91),尤其在成熟T/NK细胞非霍奇金淋巴瘤中(HR 0.46,95%CI 0.26-0.83)。
  • 成熟侵袭性B细胞非霍奇金淋巴瘤患者中广泛型cGVHD与淋巴瘤进展风险降低相关(HR 0.55,95%CI 0.31-0.97)。
  • 局限型cGVHD与更优生存相关(无进展生存:HR 0.71,95%CI 0.56-0.90),而严重GVHD对生存有负面影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The graft-versus-lymphoma (GVL) effect and its association with acute and chronic GVHD (aGVHD, cGVHD) has not been comprehensively elucidated. We retrospectively analysed 2204 Japanese patients with non-Hodgkin lymphomas (NHLs; indolent B-NHLs, n = 689; aggressive B-NHLs, n = 720; mature T/NK-NHLs, n = 795) receiving a first allo-HSCT in 2003-2017. Pre-transplant lymphoma control showed complete response (CR) in 759 and non-CR in 1445. We assessed the impact of aGVHD/cGVHD on lymphoma progression and other outcomes. Although aGVHD/cGVHD showed no statistical impact on lymphoma progression in the overall cohort, their impact was clear in certain groups: Grade I-II aGVHD in CR patients (HR, 0.63; 95% CI, 0.43-0.91), especially in mature T/NK-NHL (HR, 0.46; 95% CI, 0.26-0.83) and extensive cGVHD in patients with mature aggressive B-NHLs (HR, 0.55; 95% CI, 0.31-0.97). In total, limited cGVHD was associated with superior survivals (progression-free survival: HR, 0.71; 95% CI, 0.56-0.90), whereas severe GVHDs showed negative impacts on them. Our results support the presence of GVL effects differentially associated with GVHD in different lymphoma subtypes/controls. Meanwhile, it was also suggested that we should manage GVHDs within a limited activity, considering the negative impact of severe GVHDs. As pre-transplant lymphoma control remains a strong factor influencing transplant outcomes, improving its management is an important issue to be addressed.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Watanabe M, Kanda J, Fukuda T, et al. Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy. Br J Haematol. 2023. PMID: 37614023. doi:10.1111/bjh.19041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。